Results 91 to 100 of about 17,768 (255)
Candida infections, causes, targets and resistance mechanisms. Traditional and alternative antifungal agents [PDF]
, 2013 The genus Candida includes about 200 different species, but only a few species are human opportunistic pathogens and cause infections when the host becomes debilitated or immunocompromised. Candida infections can be superficial or invasive.
Leonardi, Darío +1 more
core +3 more sources
Rezafungin Utilisation in Real Life—FungiScope Results From Europe and the United States
Mycoses, Volume 68, Issue 9, September 2025.ABSTRACT Background Rezafungin, a novel echinocandin with once‐weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While clinical trial data support its efficacy and safety, real‐world experience remains limited.
Ilana Reinhold +24 more
wiley +1 more source
Echinocandins for candidemia: a rational choice
Reviews in Health Care, 2013 Among antifungal drugs, echinocandins (micafungin, caspofungin and anidulafungin) represent a rational choice for the first-line therapy of candidemia/invasive candidiasis in critically ill patients. Among other properties characterizing echinocandins, it’s important to emphasize the broad spectrum of activity, the fungicidal activity against the ...
Menichetti, Francesco +1 more
openaire +4 more sources
Mycoses, Volume 68, Issue 9, September 2025.ABSTRACT Introduction Candidaemia is a life‐threatening infection with a persistently high mortality rate, despite significant advances in antifungal therapy and supportive care. The European Confederation of Medical Mycology developed the EQUAL Candida Score as a standardised tool to evaluate adherence to guideline‐based management; however, its ...
Elif Mukime Saricaoglu +9 more
wiley +1 more source
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America [PDF]
, 2017 Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America.
Andes, David +13 more
core
Transplant Infectious Disease, Volume 27, Issue 5, September/October 2025.ABSTRACT The case discussed involves a 41‐year‐old Italian man who was a candidate for chimeric antigen receptor T‐cell therapy (CAR‐T) for mediastinal diffuse large B‐cell lymphoma. His CAR‐T treatment was postponed several times due to prolonged relapsing COVID‐19 and new onset of pulmonary Mycobacterium tuberculosis diseases.
Monica Melchio +10 more
wiley +1 more source
Cell wall perturbation sensitizes fungi to the antimalarial drug chloroquine. [PDF]
, 2013 Journal ArticleResearch Support, Non-U.S. Gov'tCopyright © 2015 by the American Society for Microbiology.Post print version deposited in accordance with SHERPA RoMEO guidelines.Chloroquine (CQ) has been a mainstay of antimalarial drug treatment for ...
Avery, SV +5 more
core +5 more sources
Antimicrobial activity, synergism and inhibition of germ tube formation by Crocus sativus-derived compounds against Candida spp [PDF]
, 2016 The limited arsenal of synthetic antifungal agents and the emergence of resistant Candida strains have prompted the researchers towards the investigation of naturally occurring compounds or their semisynthetic derivatives in order to propose new ...
ANGIOLELLA, Letizia +4 more
core +2 more sources
Hsp21potentiates antifungal drug tolerance in Candida albicans [PDF]
, 2013 Peer reviewedPublisher ...
Alix Therese Coste +52 more
core +2 more sources
Clinical Case Reports, Volume 13, Issue 8, August 2025.ABSTRACT Pneumocystis jirovecii pneumonia (PJP) is a potential life‐threatening opportunistic infection that predominantly affects immunocompromised individuals, such as those with human immunodeficiency virus or organ transplant recipients. The treatment of PJP, particularly severe cases, remains challenging, as standardized treatment therapies often ...
Hongtao Hu +5 more
wiley +1 more source